| Features: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Benzyl isothiocyanate Benzyl isothiocyanate (BITC) is a naturally occurring aromatic isothiocyanate and electrophilic organosulfur phytochemical generated from the glucosinolate glucotropaeolin by myrosinase-mediated hydrolysis. Isothiocyanates (pid 476) is its parent chemical class. Natural dietary sources include nasturtium, garden cress, papaya and other plants containing benzyl glucosinolate. BITC has substantial mechanistic and animal anticancer evidence distinct from other isothiocyanates, particularly involving mitochondrial ROS generation, apoptosis, cell-cycle arrest and suppression of STAT3-dependent tumor signaling. It is not an approved anticancer drug and currently lacks convincing human cancer efficacy data. Primary mechanisms (ranked):
Bioavailability / PK relevance: BITC is orally absorbed and extensively metabolized through glutathione conjugation and the mercapturic-acid pathway. Human studies demonstrate urinary excretion of BITC-derived mercapturic-acid metabolites, with one oral study recovering approximately 54% of administered BITC as the major urinary metabolite and most excretion occurring within approximately 10–12 hours. After consumption of benzyl-glucosinolate-containing nasturtium, BITC metabolites and protein conjugates have been detected in plasma, urine and breath. Free BITC exposure is limited by rapid metabolism, chemical reactivity and protein conjugation. Pharmacokinetic characterization at proposed therapeutic anticancer doses remains inadequate. In-vitro vs systemic exposure relevance: Many anticancer experiments use BITC concentrations in the low-micromolar range, commonly approximately 2.5–10 µM. Some investigators describe low-micromolar concentrations as potentially plasma-achievable, but robust human pharmacokinetic data demonstrating sustained free BITC at concentrations used in cancer-cell experiments are lacking. Consequently, direct translation of prolonged in-vitro exposure to oral human dosing remains uncertain. Protein binding/conjugation and rapid mercapturic-acid metabolism further reduce freely available BITC. Clinical evidence status: Preclinical. There is extensive cancer-cell evidence and multiple animal studies demonstrating tumor-growth, angiogenesis and metastasis suppression. Human studies establish dietary absorption and metabolism but do not establish anticancer efficacy. No convincing completed clinical trial of BITC itself as a cancer treatment or chemopreventive intervention was identified. BITC should therefore be distinguished from phenethyl isothiocyanate (PEITC), which has entered human cancer-prevention trials. Safety / translation: Dietary exposure and use as a food flavouring are substantially different from pharmacologic anticancer dosing. JECFA concluded that BITC presented no safety concern at current flavouring-use exposure, but concentrated therapeutic exposure has not been adequately established as safe. BITC is highly electrophilic and concentrated material is an eye and respiratory irritant. Experimental genotoxic effects have been reported at concentrations or doses substantially above normal human dietary exposure. These findings support caution against extrapolating food-level safety to high-dose supplementation. Benzyl Isothiocyanate Mechanistic Profile
TSF: P: 0–30 min R: 30 min–3 hr G: >3 hr |
| 9231- | ITCs, | Cisplatin, | AITC, | BITC, | Isothiocyanates inhibit the cisplatin-induced apoptosis and inflammation in human kidney HEK-293 cells |
| - | in-vitro, | Nor, | HEK293 |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:530 Target#:% State#:% Dir#:%
wNotes=0 sortOrder:rid,rpid